Transgenic Medicine (Antithrombins)

ATIII Found Safe in Clinical Trial

Published in Gene Therapy Weekly, November 4th, 1996

Genzyme Transgenics Corp., Framingham, Massachusetts, announced that results from a Phase I trial conducted in the United Kingdom (U.K.) showed that the transgenic form of antithrombin III (ATIII) raised no safety issues in healthy subjects.

ATIII is a plasma protein that helps prevent harmful blood clotting in many serious medical conditions. The company also announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration for a Phase II trial in the United States later in 1996. The Phase II trial is aimed at a reduction in bleeding and in the amount of donor blood needed by patients undergoing coronary artery...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1996-11-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry